Recurrent Wilms Tumor and Other Childhood Kidney Tumors Clinical Trial
Official title:
Categorization of Wilms Tumors by Genetic Expression
This laboratory study is using gene expression profiling to identify different categories of Wilms tumors. Studying the genes expressed in samples of tumor tissue from patients with cancer may help doctors identify biomarkers related to cancer.
OBJECTIVES:
I. Identify new molecular categories of Wilms tumor (WT) based on the gene expression
profiles of samples from patients with this disease.
II. Develop a classifying system (classifier) that will predict a defined number of
clinically relevant categories based on expression of an established set of genes.
III. Confirm and test the classifier with further analysis of the genes by several different
methodologies, using additional patient samples that are outside of the case/cohort but
which possess the clinically or scientifically relevant parameter.
IV. Validate the use of the classifier to predict defined groups within a second set of
samples (for which investigators are blinded to the clinical and biological data) by
subsequent comparison with true incidence of pertinent markers.
OUTLINE:
Three hundred tumor specimens are analyzed for genetic expression profiles using Affymetrix
assays. Specific genes are identified as classifiers and analyzed using tissue arrays. An
additional 300 specimens are examined for gene expression and categorized according to the
classifiers.
;
Observational Model: Cohort, Time Perspective: Retrospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01118078 -
Biomarkers in Tissue Samples From Patients With High-Risk Wilms Tumor
|
N/A | |
| Completed |
NCT01305200 -
Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant
|
Phase 3 | |
| Completed |
NCT00101270 -
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
|
Phase 1 | |
| Completed |
NCT01614808 -
Studying Biomarkers in Urine Samples From Younger Patients With Wilms Tumor
|
N/A | |
| Completed |
NCT01502410 -
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
|
Phase 2 | |
| Completed |
NCT00831844 -
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors
|
Phase 2 | |
| Active, not recruiting |
NCT00638898 -
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
|
Phase 1 | |
| Completed |
NCT01586104 -
Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases
|
N/A | |
| Completed |
NCT00331643 -
Ixabepilone in Treating Young Patients With Refractory Solid Tumors
|
Phase 2 | |
| Completed |
NCT00309907 -
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
|
Phase 2 | |
| Completed |
NCT00012181 -
Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
|
Phase 1 |